Commercializing Core Cell-free DNA Technology Beyond Reproductive Health
SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, will share data and roadmap for its emerging businesses in renal transplantation and oncology, during an investor call on June 27, 2018.
June 27, 2018
1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In US/Canada:
Live Dial-In US/ Canada/
A webcast replay will be available at investor.natera.com.
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer and organ transplantation including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter.
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Barbara Sullivan, Sullivan & Associates, 714-374-6174, email@example.com
SOURCE Natera, Inc.